TEZSPIRE Comprehensive Forecast on the Accelerating Market Growth for Asthma, Rhinosinusitis, COPD, Eosinophilic Esophagitis and Chronic Urticaria Infections by 2034

AI Briefing

• – TEZSPIRE is a monoclonal antibody targeting the interleukin-13 pathway, approved for asthma, rhinosinusitis, and chronic urticaria; The market is expected to grow due to the increasing prevalence of these conditions; The forecast projects a CAGR of 8.5% from 2022 to 2034.